Connection

Raymond DuBois to Cyclooxygenase 2

Back to Details
This is a "connection" page, showing publications Raymond DuBois has written about Cyclooxygenase 2.
Raymond DuBois
Connection Strength
4.685
Cyclooxygenase 2
  1. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 12; 161(6):1813-1829.
    View in: PubMed
    Score: 0.715
  2. The role of the PGE2-aromatase pathway in obesity-associated breast inflammation. Cancer Discov. 2012 Apr; 2(4):308-10.
    View in: PubMed
    Score: 0.370
  3. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
    View in: PubMed
    Score: 0.320
  4. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007; 58:239-52.
    View in: PubMed
    Score: 0.257
  5. Connecting COX-2 and Wnt in cancer. Cancer Cell. 2006 Jan; 9(1):6-8.
    View in: PubMed
    Score: 0.240
  6. Ras up-regulation of cyclooxygenase-2. Methods Enzymol. 2006; 407:401-10.
    View in: PubMed
    Score: 0.240
  7. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle. 2004 Dec; 3(12):1512-5.
    View in: PubMed
    Score: 0.223
  8. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas. Cancer Prev Res (Phila). 2022 05 03; 15(5):285-296.
    View in: PubMed
    Score: 0.186
  9. Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology. 2020 03; 158(4):971-984.e10.
    View in: PubMed
    Score: 0.157
  10. Peroxisome proliferator-activated receptor d promotes colonic inflammation and tumor growth. Proc Natl Acad Sci U S A. 2014 May 13; 111(19):7084-9.
    View in: PubMed
    Score: 0.107
  11. Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc. 2014; 125:358-72; discussion 372-3.
    View in: PubMed
    Score: 0.105
  12. Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry. PLoS One. 2013; 8(4):e61379.
    View in: PubMed
    Score: 0.100
  13. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas. 2013 Apr; 42(3):467-74.
    View in: PubMed
    Score: 0.099
  14. Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-eicosatetraenoic acid by rat intestinal epithelial cells. Chem Res Toxicol. 2007 Nov; 20(11):1665-75.
    View in: PubMed
    Score: 0.068
  15. MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism. Dig Dis Sci. 2007 Oct; 52(10):2757-65.
    View in: PubMed
    Score: 0.065
  16. NSAIDs and prostate cancer risk. Cancer J. 2006 Mar-Apr; 12(2):108-9.
    View in: PubMed
    Score: 0.061
  17. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology. 2005; 69 Suppl 1:28-32.
    View in: PubMed
    Score: 0.059
  18. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology. 2005 Aug; 129(2):577-90.
    View in: PubMed
    Score: 0.058
  19. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005 Apr 20; 23(12):2840-55.
    View in: PubMed
    Score: 0.057
  20. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005 Mar 01; 65(5):1822-9.
    View in: PubMed
    Score: 0.057
  21. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005 Jan 10; 23(2):254-66.
    View in: PubMed
    Score: 0.056
  22. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005 Feb 04; 280(5):3217-23.
    View in: PubMed
    Score: 0.055
  23. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology. 2004 Nov; 127(5):1391-400.
    View in: PubMed
    Score: 0.055
  24. Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4266s-4269s.
    View in: PubMed
    Score: 0.054
  25. Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture. Chest. 2004 May; 125(5 Suppl):134S-40S.
    View in: PubMed
    Score: 0.053
  26. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004 May-Jun; 10(3):145-52.
    View in: PubMed
    Score: 0.053
  27. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):12-21.
    View in: PubMed
    Score: 0.053
  28. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):64-73.
    View in: PubMed
    Score: 0.053
  29. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):415-6.
    View in: PubMed
    Score: 0.052
  30. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging. Mol Imaging Biol. 2003 Sep-Oct; 5(5):286-303.
    View in: PubMed
    Score: 0.051
  31. Will an aspirin a day keep the endoscope away? Gastroenterology. 2003 Aug; 125(2):612-4.
    View in: PubMed
    Score: 0.051
  32. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003 Sep 12; 278(37):35451-7.
    View in: PubMed
    Score: 0.050
  33. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. Clin Cancer Res. 2003 May; 9(5):1577-8.
    View in: PubMed
    Score: 0.050
  34. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerg Drugs. 2003 May; 8(1):1-7.
    View in: PubMed
    Score: 0.050
  35. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003 Mar 01; 63(5):906-11.
    View in: PubMed
    Score: 0.049
  36. Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res. 2003; 37:124-37.
    View in: PubMed
    Score: 0.049
  37. New agents for cancer prevention. J Natl Cancer Inst. 2002 Dec 04; 94(23):1732-3.
    View in: PubMed
    Score: 0.049
  38. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2002 Jun 01; 62(11):3282-8.
    View in: PubMed
    Score: 0.047
  39. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst. 2002 Mar 20; 94(6):406-7.
    View in: PubMed
    Score: 0.046
  40. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002; 42:55-80.
    View in: PubMed
    Score: 0.045
  41. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002; 53:35-57.
    View in: PubMed
    Score: 0.045
  42. Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol. 2008 Dec; 39(6):689-96.
    View in: PubMed
    Score: 0.018
  43. Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J Biol Chem. 2005 Oct 21; 280(42):35562-70.
    View in: PubMed
    Score: 0.015
  44. Cyclooxygenase-2-mediated DNA damage. J Biol Chem. 2005 Aug 05; 280(31):28337-46.
    View in: PubMed
    Score: 0.014
  45. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Surgery. 2003 May; 133(5):568-79.
    View in: PubMed
    Score: 0.012
  46. New avenues for the prevention of colorectal cancer: targeting cyclo-oxygenase-2 activity. Best Pract Res Clin Gastroenterol. 2002 Dec; 16(6):945-56.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.